Profil
Mr. Isaac Stoner is a Chief Executive Officer & Director at Mindimmune Therapeutics, Inc. He is on the Board of Directors at Mindimmune Therapeutics, Inc. Mr. Stoner was previously employed as a President, Chief Executive Officer & Director by Octagon Therapeutics, Inc. He received his undergraduate degree from Brown University and an MBA from MIT Sloan School of Management.
Aktiva positioner av Isaac Stoner
| Företag | Position | Start |
|---|---|---|
Mindimmune Therapeutics, Inc.
Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs that target immune system for treating diseases related to central nervous system | Verkställande Direktör | 2025-11-24 |
Tidigare kända positioner av Isaac Stoner
| Företag | Position | Slut |
|---|---|---|
Octagon Therapeutics, Inc.
Octagon Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotics and medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells | Verkställande Direktör | 2025-01-02 |
Isaac Stoners utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIT Sloan School of Management
MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mindimmune Therapeutics, Inc.
Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs that target immune system for treating diseases related to central nervous system | Health Technology |
Octagon Therapeutics, Inc.
Octagon Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotics and medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells | Health Technology |
















